Erythropoietic Protoporphyria (EPP) Treatment Market Critical Insights, TrendsPosted by AayushFMR on March 23rd, 2021 Porphyria is a genetic metabolic disorder with inborn error of heme biosynthesis. Heme is essential component of blood cells which carry oxygen and support in breaking down chemical compounds in the liver. Erythropoietic protoporphyria (EPP) is a type of porphyria which is a rare disease associated with an impaired activity of ferrocheletase (FECH) an important enzyme in heme production. The worldwide reported prevalence for Erythropoietic protoporphyria is rages from 1 in 75,000 to 1 in 200,000 and it is the most common porphyria in children. Drug therapies used to treat Erythropoietic protoporphyria (EPP) includes antihistamines, analgesics, hormonal therapy, phototherapy, sunscreens, and antioxidants. Hormonal therapy is a recent emerging treatment in an erythropoietic protoporphyria (EPP) treatment market approved by the US FDA. Erythropoietic Protoporphyria (EPP) Treatment Market: Drivers and Restraints The significantly increasing unmet need of advanced erythropoietic protoporphyria (EPP) treatment therapeutics for the treatment of erythropoietic protoporphyria (EPP) is expected to propel the growth of the global erythropoietic protoporphyria (EPP) treatment market. In addition, growing prevalence of erythropoietic protoporphyria (EPP) in children is expected to fuel the growth of erythropoietic protoporphyria (EPP) treatment market. Novel therapeutic development and approval is expected to propel an erythropoietic protoporphyria (EPP) treatment market in the future. However, higher treatment cost and lack of standardize healthcare facilities are the key factors expected to slow down the growth of erythropoietic protoporphyria (EPP) treatment market in the emerging economies. To remain ‘ahead’ of your competitors, request for a sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=4717 Erythropoietic Protoporphyria (EPP) Treatment Market: Segmentation An erythropoietic protoporphyria (EPP) treatment market can be segmented into therapy type, distribution channels and geography. Based on therapy type, the global erythropoietic protoporphyria (EPP) treatment market is segmented as:
Based on the distribution channels, the global erythropoietic protoporphyria (EPP) treatment market is segmented as:
Erythropoietic Protoporphyria (EPP) Treatment Market: Overview An erythropoietic protoporphyria (EPP) treatment market is expected to experience moderate growth over the forecast period owing to technical advancements in the diagnosis and treatment of an erythropoietic protoporphyria (EPP). Leading developers are focusing on development of novel therapeutics for erythropoietic protoporphyria (EPP). Among therapy types, first-line hormonal therapies segment is expected to hold the major market share in an erythropoietic protoporphyria (EPP) treatment market. Recently, in last quarter of 2019, FDA has approved Scenesse® (afamelanotide subcutaneous implant) a new treatment for erythropoietic protoporphyria (EPP) manufactured by the Clinuvel Pharmaceuticals ALS, Australia. Among distribution channels segment, retail pharmacy segment is expected to be the leading revenue generating segment owing to high patient foot fall in erythropoietic protoporphyria (EPP) treatment market. Erythropoietic Protoporphyria (EPP) Treatment Market: Regional Outlook Geographically, global erythropoietic protoporphyria (EPP) treatment market is segmented into seven key regions viz. North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa. North America is a prominent region in an erythropoietic protoporphyria (EPP) treatment market owing to novel treatment advancements. European erythropoietic protoporphyria (EPP) treatment market is a second most lucrative region due to early diagnosis and treatment adoption. In addition, East Asia region substantially has higher market growth rate owing to large base of population. Middle East and Africa is expected to be least-lucrative market owing to poor healthcare infrastructure and low awareness. Erythropoietic Protoporphyria (EPP) Treatment Market: Key Players The global market for erythropoietic protoporphyria (EPP) treatment is consolidated with few market players. Examples of some of the primary key players operating in the global erythropoietic protoporphyria (EPP) treatment market are Clinuvel Pharmaceuticals ALS, Johnson and Johnson, Tishcon Corp., L'Oréal S.A., Fenton Pharmaceuticals Ltd., In-Life Co. Pfizer Inc., Mylan N.V., Teva Pharmaceuticals, Sun Pharma Ltd., and among others. About Fact.MR Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner. Contact: Corporate Headquarter: Like it? Share it! More by this author |